This article is more than 5 years old. Information may no longer be current.
Alberta research fund aims to advance diabetes discoveries
Click Here to Manage Email Alerts
A new collaboration between the Alberta Diabetes Institute at the University of Alberta and Janssen Inc. in Canada will support research in type 1 and type 2 diabetes, specifically focused on novel research with potential for commercialization.
The 3-year, $600,000, competitive Johnson & Johnson Diabetes Research Fund — backed by Janssen along with the Government of Alberta and the Alberta Diabetes Foundation — aims to advance early stage technologies related to diabetes.
“This collaboration of funding partners exemplifies the good will of the private, public and philanthropic organizations to work together to best serve patients,” Douglas Miller, MD, CM, FRCPC, dean of the Faculty of Medicine & Dentistry at the University of Alberta, said in a press release.
The Alberta Diabetes Institute and technical experts from Johnson & Johnson Innovation Center in California will identify high-potential opportunities from medical researchers across the Canadian province and award up to $50,000 for a year.
All research around diabetes is eligible for the funding. The collaboration expects to receive proposals that lead to development of drugs, devices and cell therapies, as well as diagnosis, treatment and management of type 1 and type 2 diabetes.